Story
S&P Upgrades Teva to Investment Grade on Debt Reduction and Strong Brand Performance

S&P Global Ratings has upgraded Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) to investment grade, raising its issuer credit rating to 'BBB-' from 'BB+' with a stable outlook. The ratings agency cited the company's successful deleveraging efforts, stabilizing generics business, and strong performance from its portfolio of branded products as key drivers for the decision.
Deleveraging and Brand Growth Drive Confidence
According to S&P, the upgrade reflects Teva's improved financial health and operating performance. The company has made significant strides in strengthening its balance sheet, reducing its gross debt from nearly $29 billion in 2018 to about $17 billion in 2025.
The ratings agency highlighted several key factors supporting its decision:
- Leverage Reduction: Teva is on a trajectory to lower its leverage to the mid-3x range by the end of the year, down from 4x in the second quarter. S&P expects the company to use its strong cash flow to continue paying down debt, targeting a 2x net leverage ratio.
- Branded Product Strength: Teva’s innovative brands, including Austedo, Ajovy, and Uzedy, are delivering substantial growth. These products generated over $3.1 billion in revenue in 2025 and saw collective growth of 43% in the second quarter of 2026.
- Strong Cash Flow: S&P forecasts Teva will generate annual adjusted free operating cash flow of $2.3 billion to $2.5 billion. The majority of this is expected to be directed toward repaying maturing debt.
- Cost Management: The company is effectively executing its cost-savings plan, with nearly $500 million in annualized savings anticipated in 2026 toward a goal of $700 million by 2027.
AdFuture Outlook and Pipeline
S&P's stable outlook is based on expectations of continued solid performance, supported by growth in higher-margin branded products and a promising pipeline. The agency projects that Teva's three key brands alone will contribute $500 million of revenue growth in 2026 and at least $200 million in 2027.
Potential future growth is also supported by several late-stage pipeline assets, including olanzapine LAI (2026) and ecopipam (2027). However, the outlook also accounts for expected competitive pressures on its generic Revlimid in 2026 and on Austedo in 2027.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.